DiaMedica Therapeutics
DMAC
32 hedge funds and large institutions have $14.9M invested in DiaMedica Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 3 closing their positions.
17% more capital invested
Capital invested by funds: $12.7M → $14.9M (+$2.2M)
1.22% more ownership
Funds ownership: 12.12% → 13.34% (+1.2%)
0% more funds holding
Funds holding: 32 → 32 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
0% more call options, than puts
Call options by funds: $8K | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
+$1.42M |
| 2 |
BL
Bleichroeder LP
New York
|
+$439K |
| 3 |
LPL Financial
San Diego,
California
|
+$48K |
| 4 |
MCA
Magnolia Capital Advisors
Jackson,
Mississippi
|
+$27.4K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$455K |
| 2 |
Bank of New York Mellon
New York
|
-$66.5K |
| 3 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
-$47.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$42.8K |
| 5 |
First Manhattan
New York
|
-$30.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $5.57K | -$2.22K | -808 | -30% |
|
|
TWC
27
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $3.12K | – | – | – |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$579 | +211 | +25% |
|
|
LFA
29
Legend Financial Advisors
Pittsburgh,
Pennsylvania
| $2.95K | – | – | – |
|
|
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $679 | – | – | – |
|
31
Bank of America
Charlotte,
North Carolina
| $540 | +$502 | +183 | New |
|
32
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $71 | – | – | – |
|
|
33
Bank of New York Mellon
New York
| – | -$66.5K | -24,000 | Closed |
|
34
UBS Group
Zurich,
Switzerland
| – | -$5.33K | -1,926 | Closed |
|
35
Wells Fargo
San Francisco,
California
| – | -$485 | -175 | Closed |
|
DMAC Hedge Fund Activity: Q2 2024 in Review
32 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2024, worth a combined $14.9M — up 17% from $12.7M a quarter earlier.
Fund positioning in DMAC was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 9 trimmed.
The largest buyer was Cooperman Leon G, adding an estimated $1.42M. The largest seller was Susquehanna International Group, cutting an estimated $455K.
- 32 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $14.9M of DiaMedica Therapeutics stock for Q2 2024, up 17% quarter-over-quarter.
- 3 funds opened new DiaMedica Therapeutics positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest DiaMedica Therapeutics buyer in Q2 2024 was Cooperman Leon G, an estimated $1.42M added.
- The largest DiaMedica Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $455K sold.
Based on aggregated 13F filings for Q2 2024.